Navigation Links
UMass Medical School researchers receive $8.5M grant award to fight AIDS
Date:10/24/2007

WORCESTER, Mass. As the HIV/AIDS epidemic continues around the globe laying claim to more than 25 million lives and infecting over 39 million, researchers continue to search for both a cure and improved treatments for those suffering with this disease. Now the leading cause of death worldwide among 15 to 59 year olds, AIDS is a remarkably resilient adversary with the potent ability to evolve rapidly. This evolution dramatically complicates treatment, decreasing the effectiveness of existing drugs and necessitating the continual development of new therapeutics. University of Massachusetts Medical School Professor of Biochemistry & Molecular Pharmacology Celia A. Schiffer, PhD, is at the forefront of investigations to elucidate how HIV develops resistance to current drugs.

As a principal investigator of a National Institutes of Health Institute of General Medical Sciences Program Project Grant first awarded in 2001, Dr. Schiffer has comprised a stellar team of scientists from around the nation to develop HIV drugs that are less vulnerable to drug resistance. In recognition of the success of her efforts, Schiffer was recently awarded a full, five-year renewal of the project, Targeting Ensembles of Drug Resistant HIV-Protease. The renewal, totaling more than $8.5 million, will speed studies that seek a better understanding of inhibitor recognition and the development of new methodologies for designing inhibitors against HIV and other viruses and infections that have a propensity for acquiring drug resistance.

According to Terry R. Flotte, MD, executive deputy chancellor of UMMS and dean of the School of Medicine, the renewal reflects the NIHs confidence in Schiffers scientific aims. This work clearly illustrates how the advance of molecular biology can lead to direct benefit to patients. Dr. Schiffer's efforts to define exactly how HIV can become resistant to current drugs are vital to the development of better strategies to control HIV/AIDS.

While highly active antiretroviral treatment (HAART) including inhibitors that target HIV-1 proteasea protein that allows viral maturation through cutting and releasing key viral components in the immature virushas been remarkably successful in decreasing mortality, the emergence of mutations of HIV-1 that are resistant to current drug regimens is a critical factor in the clinical failure of antiviral therapy. With this renewed funding, Schiffer and colleagues will continue to address this challenge with a comprehensive approach that integrates clinical data, structural biology and biophysical chemistry, medical informatics and biostatistics, biochemistry and molecular virology, computational chemistry and computer-aided design, and synthetic and medicinal chemistry. The integrated program embraces two overarching goals: to clarify the role of compensatory mutations in HIV-1 protease in conferring drug resistance and to develop new HIV-1 protease inhibitors that are more robust against drug resistance.

The occurrence of drug resistance negatively impacts the lives of millions of patients by limiting the longevity of many of our most promising new drugs. Through this integrated approach, we look forward to contributing to the development of drugs that promise to be more effective against HIV. Importantly, the new strategies we develop may also reduce drug resistance in other quickly evolving diseases, including lung cancer and hepatitis C, Schiffer said.

To date, Schiffer and collaborators have made a number of advances. In 2004, for example, they were able to determine the crystal structures of many of the substratesthe sites HIV-1 protease cuts in the immature virus allowing viral maturationand to compare their shape with the existing drugs. They found that while the sequences of the sites that are cuts were different, they all fit within a similar space, which they dubbed the substrate envelope. Significantly, the investigators found that most of the currently used inhibitors protrude beyond the substrate envelope, and many mutations that cause drug resistance occur where the inhibitors protrude away from the substrates. Drug resistance occurs since mutations at these positions limit drug binding, but allow HIV-1 protease to continue to function by recognizing and cutting substrates, thereby permitting the virus to mature.

In 2006, expanding upon this work the investigators reported on a new strategy to reduce the probability of drug resistance, by designing and synthesizing novel inhibitors to fit within the substrate envelope. This strategy should greatly retard the occurrence of drug resistance as any mutation that would confer drug resistance would simultaneously impact substrate recognition, thereby preventing HIV protease from functioning. Thus inhibitors developed by this method should be more robust against resistance occurring. Confirming the validity of this strategy, the scientists have designed, synthesized and are evaluating a novel series of highly potent HIV protease inhibitors that appear promising against drug resistant variants of HIV protease.


'/>"/>

Contact: Kelly Bishop
kelly.bishop@umassmed.edu
508-856-2000
University of Massachusetts Medical School
Source:Eurekalert

Related biology news :

1. UCLA Study Shows One-Third of Drug Ads in Medical Journals Do Not Contain References Supporting Medical Claims
2. Automatic extraction of gene/protein biological functions from biomedical text
3. Vital step in cellular migration described by UCSD medical researchers
4. Breakthrough method in nanoparticle synthesis paves the way for new pharmaceutical and biomedical applications
5. Medical molecules designed to respond to visible light that can penetrate tissue
6. Medical whistleblowers speak out
7. UCSD medical/bioengineering reseachers show titanium debris satobtage artificial joints
8. Innovative coating could give medical implants a longer life
9. Natural tumor suppressor in body discovered by UCSD medical researchers
10. Protein synthesis can be controlled by light, opening way for new scientific, medical applications
11. Modified collagen could yield important medical applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/1/2016)... , Feb. 1, 2016  Today, the first ... (AHA) announced plans to develop a first of its ... power of IBM Watson. In the first application of ... IBM (NYSE: IBM ), and Welltok will create ... health assessments with cognitive analytics, delivered on Welltok,s health ...
(Date:1/25/2016)... 25, 2016  Glencoe Software, the world-leading supplier of ... industries, will provide the data management solution OMERO Plus ... Photo - ... Phenotypic analysis measures the characteristics and ... comparisons between states such as health and disease, the ...
(Date:1/20/2016)... 20, 2016   MedNet Solutions , an innovative ... of clinical research, is pleased to announce the attainment ... are the result of the company,s laser focus on ... , it,s comprehensive, easy-to-use and highly affordable cloud-based ... Key MedNet growth achievements in 2015 include: ...
Breaking Biology News(10 mins):
(Date:2/11/2016)...   BioInformant announces the February 2016 release ... Opportunities, Tools, and Technologies – Market Size, Segments, Trends, ... The first and only market ... BioInformant has more than a decade of historical information ... stem cell type. This powerful 175 page global strategic ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... cell treatment clinic in Quito, Ecuador. The new facility will provide advanced protocols ... patients from around the world. , The new GSCG clinic is headed ...
(Date:2/10/2016)... Feb. 10, 2016  The Maryland House of Delegates ... announced that University of Maryland School of Medicine Dean ... University of Maryland Medical System President and CEO ... Medallion," the highest honor given to the public by ... Dean Reece and Mr. Chrencik for their ...
(Date:2/10/2016)... New York, and New York, New York (PRWEB) , ... ... ... Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) today announced that it ... and develop new vaccines and immunotherapies for infectious diseases and cancer. ...
Breaking Biology Technology: